Genetic Technologies Limited

LSE:0A4N Stock Report

Market Cap: US$3.5m

Genetic Technologies Past Earnings Performance

Past criteria checks 0/6

Genetic Technologies's earnings have been declining at an average annual rate of -16.6%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 53.5% per year.

Key information

-16.6%

Earnings growth rate

17.5%

EPS growth rate

Life Sciences Industry Growth36.9%
Revenue growth rate53.5%
Return on equity-656.5%
Net Margin-124.2%
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Genetic Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0A4N Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2410-12121
31 Mar 2410-12111
31 Dec 2310-13111
30 Sep 2310-12111
30 Jun 2310-12111
31 Mar 2311-10111
31 Dec 2211-9111
30 Sep 2210-8111
30 Jun 229-7101
31 Mar 227-791
31 Dec 215-770
30 Sep 213-761
30 Jun 211-761
31 Mar 212-760
31 Dec 200-762
30 Sep 200-752
30 Jun 201-641
31 Mar 200-642
31 Dec 190-642
30 Sep 190-642
30 Jun 190-642
31 Mar 190-642
31 Dec 180-543
30 Sep 180-542
30 Jun 180-542
31 Mar 180-752
31 Dec 170-852
30 Sep 170-852
30 Jun 171-862
31 Mar 171-863
31 Dec 161-863
30 Sep 161-863
30 Jun 161-863
31 Mar 161-872
31 Dec 151-872
30 Sep 152-983
30 Jun 152-993
31 Mar 153-993
31 Dec 144-1093
30 Sep 144-1093
30 Jun 145-1093
31 Mar 144-10103
31 Dec 134-11103

Quality Earnings: 0A4N is currently unprofitable.

Growing Profit Margin: 0A4N is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0A4N is unprofitable, and losses have increased over the past 5 years at a rate of 16.6% per year.

Accelerating Growth: Unable to compare 0A4N's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0A4N is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-1.4%).


Return on Equity

High ROE: 0A4N has a negative Return on Equity (-656.53%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 04:16
End of Day Share Price 2024/10/15 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genetic Technologies Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Marc KennisAPP Securities Pty Ltd.
Kevin DeGeeterLadenburg Thalmann & Company
Chris KallosMST Financial Services Pty Limited